RecruitingPhase 1NCT06075810

A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer

A Phase 1 Open-Label, First-in-Human Trial of Oral MBQ-167 as Single Agent in Participants With Advanced Breast Cancer

Sponsor

MBQ Pharma

Enrollment

48 participants

Start Date

Nov 9, 2023

Study Type

INTERVENTIONAL

Conditions

Breast Cancer Breast Neoplasm Breast Cancer Stage IV

Summary

A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.

Eligibility

Min Age: 21 Years

Plain Language Summary

Simplified for easier understanding

This study is testing an oral drug called MBQ-167 in people with advanced breast cancer that has already been treated with approved therapies. It is an early-phase study to assess how safe and effective this new drug is. **You may be eligible if...** - You have advanced breast cancer confirmed by tissue or cell testing - Your cancer has continued to grow despite receiving approved treatments - You meet other medical criteria assessed by the study investigator **You may NOT be eligible if...** - Your breast cancer has not been previously treated - You have another serious medical condition that would make participation unsafe - You do not meet additional criteria evaluated by the study team Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.